{"nctId":"NCT01152190","briefTitle":"A Study in Benign Prostatic Hyperplasia","startDateStruct":{"date":"2010-09"},"conditions":["Benign Prostatic Hyperplasia"],"count":97,"armGroups":[{"label":"5 milligrams (mg) Tadalafil","type":"EXPERIMENTAL","interventionNames":["Drug: Tadalafil"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tadalafil","otherNames":["Cialis","LY450190"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Present with benign prostatic hyperplasia\n* Provide signed informed consent at the screening\n* Agree not to use other treatment for Benign Prostatic Hyperplasia, Erectile Dysfunction or Overactive Bladder (including herbal treatments) during the study\n\nExclusion Criteria\n\n* Have prostatic cancer or are being treated for cancer.\n* Any condition that may negatively influence the transrectal ultrasound.\n* Are being treated for heart disease with any drug that is called a nitrate (for example, nitroglycerin).\n* Any evidence of moderate to severe cardiac disease\n* Have had any of the following in the past 90 days: chest pain (called unstable angina or angina) that requires treatment, heart attack also known as myocardial infarction, heart bypass surgery (called coronary artery bypass graft surgery), had a procedure to open up blood vessels in the heart know as angioplasty or stent placement (percutaneous coronary intervention), positive cardiac stress test without effective cardiac intervention.\n* Have very high or very low blood pressure.\n* Have uncontrolled diabetes.\n* Have certain problems with your kidneys, liver, or nervous system.","healthyVolunteers":false,"sex":"MALE","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone","description":"Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to blood flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.006"},{"groupId":"OG001","value":"0.00","spread":"0.006"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 4-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone","description":"Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.006"},{"groupId":"OG001","value":"0.01","spread":"0.006"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 4 and 8 Weeks in Arterial Resistive Index (RI) in the Prostate Peripheral Zone and Bladder Neck","description":"Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.006"},{"groupId":"OG001","value":"0.01","spread":"0.007"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.006"},{"groupId":"OG001","value":"0.01","spread":"0.007"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.012"},{"groupId":"OG001","value":"0.01","spread":"0.012"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.015"},{"groupId":"OG001","value":"0.02","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 4 and 8 Weeks in Color Pixel Intensity (CPI) in the Prostate Transition Zone, Peripheral Zone, and Bladder Neck","description":"CPI quantified blood flow in a pre-specified region of interest by using color Doppler imaging. CPI was the mean color pixel intensity in the region of interest and scores could range from 0 to 160. An increase in CPI reflected an increase in blood flow. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.21","spread":"2.377"},{"groupId":"OG001","value":"0.42","spread":"2.408"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"1.974"},{"groupId":"OG001","value":"2.53","spread":"2.083"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.48","spread":"2.059"},{"groupId":"OG001","value":"1.99","spread":"2.091"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.11","spread":"1.868"},{"groupId":"OG001","value":"2.55","spread":"1.987"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.37","spread":"4.022"},{"groupId":"OG001","value":"3.17","spread":"4.140"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"3.622"},{"groupId":"OG001","value":"7.81","spread":"3.738"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":50},"commonTop":["Headache","Abdominal pain upper","Dyspepsia","Gastric disorder","Gastrooesophageal reflux disease"]}}}